Tag Archives: Approved

oneM2M specifications approved by more than 190 ITU member countries as ITU standard to simplify IoT adoption

More than 190 ITU-T member countries have approved oneM2M specifications as ITU standard, simplifying the IoT ecosystem lifecycle by minimizing development, deployment, and maintenance costs. The ITU-T’s SG20 Internet of Things (IoT) and smart cities and communities (SC&C) approved oneM2M’s security specifications for IoT systems as part of the ITU-T Y.4500.3 series, making the entire… Read More »

Pandemic’s economic hit will be here ‘for a long time’ even if a vaccine is approved, economist says

While markets reacted positively this week to promising news of potential coronavirus vaccines in development, a top economist warned that the economic hit from the pandemic will be here for a long time. A large number of small businesses that closed in March — when restrictions around social movements went into effect — are not going to… Read More »

Tremfya (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis

Print this page HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] Tremfya is the first treatment… Read More »

Sage's postpartum depression drug is approved. Now comes the hard part

The Food and Drug Administration on Tuesday issued its first-ever approval of a postpartum depression therapy, offering a new treatment option for the roughly one in nine women who experience this kind of disorder. The question remains, however, of how accessible that option will end up being for patients. Branded as Zulresso, the therapy supplies… Read More »

Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Print this page PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel ® (dasatinib) tablets to include the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy.1 Sprycel… Read More »